finance.yahoo.com
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase visibility of these therapies but does not replace clinical guidance.
Adults with IBD, patients on biologics or considering switches, gastroenterology clinicians, and researchers tracking IBD drug outcomes.
What To Know
AbbVie presented clinical and real-world IBD data for Skyrizi (risankizumab) and Rinvoq (upadacitinib) at DDW 2026; the article summarizes one-year ASPIRE-CD results for risankizumab and real-world claims and clinical findings for upadacitinib including endoscopic improvement in perianal fistulizing Crohn’s disease.
What To Know This finance article highlights AbbVie’s presentations at Digestive Disease Week showing clinical-trial and real-world data for two IBD drugs: Skyrizi (risankizumab) and Rinvoq (upadacitinib).
It reports that risankizumab had one-year benefits in Crohn’s disease in the ASPIRE-CD study and lower treatment-switch rates in a 24-month claims analysis; Rinvoq data cited lower hospitalization/ER odds in patients who switched to it and endoscopic improvements through 52 weeks for perianal fistulizing Crohn’s disease.
The piece is written from an investment perspective, so clinical details are summarized briefly and selectively rather than reported as a full scientific result. The article does not provide detailed study methods, exact outcomes, safety data, or limitations needed to judge clinical significance.
If you want the clinical papers or full DDW abstracts, check the conference program or peer-reviewed publications for complete data.
This is a finance-focused summary of data presented at DDW; it does not substitute for the original abstracts or peer-reviewed reports. The article omits detailed methodology, safety profiles, and numerical results—consult the DDW abstracts or published studies for clinical decision-making.
